The PARADIGM International Liaison Group

Short-Term support for a long-term goal

Read more about the PILG's work

The PARADIGM International Liaison Group (PILG) is a co-creation hub acting as an operational platform to connect PARADIGM with like-minded initiatives.

These include key Innovative Medicine Initiatives and other international efforts focused on the co-development and implementation of patient engagement practices in medicines development.

The PILG supports the members of the PARADIGM consortium to create a well-defined roadmap addressing the strategic and operational needs and resources for patient engagement, focusing on the three phases targeted by PARADIGM:

Research and
priority setting

Design of
clinical trials

Early dialogues with
regulators and HTA bodies

The PILG is instrumental, agile and aligned with PARADIGM’s scope in the following ways:

provides advice to PARADIGM in developing relationships

establishes an international vision of patient engagement

reduces fragmentation and duplication

relevante of PARADIGM strategic objectives

Senior representatives of the following organisations and initiatives are a part of PILG:

+ External experts such as Dr. Violeta Stoyanova-Beninska from the Medicine Evaluation Board and chair of the Committee for Orphan Medicinal Product at the EMA and representatives from PCORI.